CAPE TOWN, SA / ACCESSWIRE / December 18, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following corporate update:
The Company is set to expand into the European market with its recently launched Medspresso™ line of CBD infused hot beverages. Medspresso™ is a premium functional beverages brand that encompasses a current product line of CBD-infused African coffees, teas and hot chocolates. The recent launch in early November has drummed up numerous inquiries from around the globe. The company is planning to ship its first international order to Cafféluxe Limited International in January 2021.
Michael Sachar, Cafféluxe Commercial Director said: “The interest has been nothing short of phenomenal. We will move the Medspresso™ range through existing distributors in the UK, Europe and GCC countries (Middle East). ”
The company is scaling up its production to meet the growing demand. Currently, the products are available at the Cafféluxe showroom and E-commerce websites across South Africa.
“The market response for Medspresso™ has been nothing short of spectacular. Consumers are loving the products and the brand. We will always work as hard as we can to earn and keep the loyalty of our consumers by delivering exceptional products far beyond expectations. ” said Wuhan General Group CEO Jeff Robinson.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™ and Handcrafted Delights™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. The Company is listed and traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
For further information:
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.
Source: Wuhan General Group, Inc./M2Bio Sciences, Inc
SOURCE: Wuhan General Group, Inc.
View source version on accesswire.com: